DelveInsight's analysis predicts significant growth in the cystic fibrosis market from 2026 to 2036, driven by the launch of emerging therapies such as Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), and others, and increased global healthcare spending. The introduction of new treatments and rising healthcare investments will expand market opportunities and improve patient outcomes.
LAS VEGAS, Oct. 21, 2026 /PRNewswire/ -- Recently published Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Cystic Fibrosis Market Summary
- The total cystic fibrosis treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest cystic fibrosis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- There were around 35K diagnosed prevalent cases of cystic fibrosis in the US in 2025, with this number projected to rise over the forecast period from 2026 to 2036.
- Leading cystic fibrosis companies, such as Spexis, Laurent Pharmaceuticals, Arcturus Therapeutics, 4D Molecular Therapeutics, Krystal Biotech, SpliSense, ReCode Therapeutics, Vertex Pharmaceuticals, and others, are developing new cystic fibrosis treatment drugs that can be available in the cystic fibrosis market in the coming years.
- The promising cystic fibrosis therapies in clinical trials include Lonodelestat, LAU-7b, ARCT-032, 4D-710, KB407, SPL84, SPL23, RCT2100, Ivacaftor, and others.
Discover the future of the cystic fibrosis therapeutics market @ https://www.delveinsight.com/report-store/cystic-fibrosis-market
Key Factors Driving the Growth of the Cystic Fibrosis Market
- Rising Prevalence of Cystic Fibrosis: The growing prevalence and continued identification of cystic fibrosis cases are expanding the overall patient pool requiring long-term treatment and disease management. Improved disease recognition and screening are also contributing to higher case detection across various regions.
- Expanding Adoption of CFTR Modulators: Increasing use of CFTR modulator therapies is a major market driver, particularly as more patients become eligible for genotype-specific treatments. Wider adoption of highly effective modulator combinations is improving clinical outcomes and supporting sustained treatment demand.
- Increasing Focus on Personalized Medicine: Greater understanding of CFTR mutations is enabling treatment strategies tailored to individual genetic profiles. The growing emphasis on precision medicine is supporting the development and adoption of mutation-specific and personalized therapeutic approaches.
- Development of Next-Generation Therapies: Pharmaceutical companies are pursuing novel therapies, including Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others. These innovations could expand treatment options for patients who remain underserved by existing therapies.
Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said, "ALYFTREK demonstrates strong clinical and commercial value, with the potential to deliver improved patient outcomes and convenient once-daily dosing, supported by rapid NHS access and reimbursement agreements that are enhancing adoption."
Cystic Fibrosis Market Analysis
- The cystic fibrosis treatment landscape is undergoing significant transformation, largely driven by the widespread adoption of CFTR modulators, which are now accessible to the majority of eligible patients. This shift is positioning cystic fibrosis increasingly as a chronic, manageable condition.
- However, substantial unmet needs remain among patients who are not eligible for CFTR modulators, while persistent disparities in global treatment access continue to influence innovation and market expansion.
- The cystic fibrosis market is largely dominated by CFTR modulators, with Vertex Pharmaceuticals maintaining a strong leadership position through its portfolio of ALYFTREK, TRIKAFTA, SYMDEKO, and ORKAMBI, which collectively contribute a significant share of global market revenues.
- Market expansion is being supported by broader access and label extensions for CFTR modulators, including their use in younger age groups and patients with a wider range of CFTR mutations.
- The market is anticipated to experience steady growth, supported by sustained uptake of established therapies and the emergence of novel treatments offering improved efficacy, broader patient coverage, and potentially disease-modifying effects.
- The evolving pipeline, which includes candidates such as Lonodelestat, LAU-7b, and ARCT-032, among others, highlights ongoing efforts to address residual unmet needs, expand treatment options, and further improve outcomes for patients with cystic fibrosis.
Cystic Fibrosis Competitive Landscape
Some of the cystic fibrosis drugs under development include Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others.
Spexis' Lonodelestat is an investigational inhaled therapy designed to inhibit neutrophil elastase, an enzyme associated with pulmonary inflammation and tissue damage in patients with cystic fibrosis. By blocking neutrophil elastase activity, Lonodelestat is intended to reduce lung inflammation and potentially preserve or improve pulmonary function. The therapy is currently being evaluated in Phase II clinical trials to assess its safety and efficacy in cystic fibrosis. Findings from these studies will help determine its potential for further development, regulatory approval, and clinical use.
Laurent Pharmaceuticals' LAU-7b (fenretinide) is a novel oral formulation of fenretinide, an atypical retinoid that modulates specific cell membrane lipids involved in viral replication and immune-inflammatory pathways. As the company's lead drug candidate, LAU-7b is a patent-protected oral formulation designed to support a convenient once-daily, low-dose treatment regimen. The candidate has completed Phase II clinical development for cystic fibrosis.
Arcturus Therapeutics' ARCT-032 is an investigational inhaled mRNA therapy delivered using LUNAR, a lipid-mediated delivery platform that encapsulates mRNA within lipid nanoparticles. In February 2024, the European Commission granted Orphan Medicinal Product Designation to ARCT-032 for the treatment of cystic fibrosis following a positive opinion from the European Medicines Agency. The candidate had previously received Rare Pediatric Disease Designation from the FDA in October 2023 and Orphan Drug Designation in November 2023. In October 2025, the company reported interim results from its ongoing Phase II clinical trial evaluating ARCT-032 in patients with cystic fibrosis.
4D Molecular Therapeutics' 4D-710 is an investigational genetic medicine candidate that utilizes the A101 vector to target the underlying cause of cystic fibrosis lung disease. The candidate is being evaluated in a Phase 1/2 clinical study in patients with cystic fibrosis who are ineligible for CFTR modulator therapy or have discontinued treatment because of adverse effects. 4D-710 is designed for single-dose aerosol administration to deliver a corrective CFTRΔR transgene throughout the airways and alveoli. Its mutation-agnostic approach is intended to provide a disease-modifying effect regardless of the patient's specific CFTR mutation.
The anticipated launch of these emerging therapies are poised to transform the cystic fibrosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cystic fibrosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the cystic fibrosis treatment pipeline @ Cystic Fibrosis Drug Pipeline
Cystic Fibrosis Epidemiology Segmentation
The cystic fibrosis epidemiology section provides insights into the historical and current cystic fibrosis patient pool and forecasted trends for the leading markets. Recent trends in cystic fibrosis indicate that Staphylococcus aureus and Pseudomonas aeruginosa remain the most prevalent pathogens, driving a large share of infections.